

EXPRESS MAIL NO.: E 15210735US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#12/Phys. Chem.
State
M&P
4/4/02

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

In re application of:

Stephen J. GARGER, *et al.*

Appl. No.: 09/626,127


Filed: July 26, 2000

Art Unit: 1656

Examiner: J. Riley

Atty. Docket: 00801.0087.CPUS04

For: **PRODUCTION OF LYSOSOMAL
ENYMES IN PLANTS BY
TRANSIENT EXPRESSION**



Information Disclosure Statement

BOX AF

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

BEST AVAILABLE COPY

herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☐ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
 - ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(i), and


- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☒ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 00801.0084.CPUS04.

Respectfully submitted,

Date: March 28, 2002


Albert P. Halluin (Reg. No. 25,227)
Viola T. Kung (Reg. No. 41,131)
Robin C. Chiang (Reg. No. 46,619)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
(650) 463-8109

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

00801.0087.CPUS04

APPLICATION NO.

09/626,127

APPLICANT

Stephen J. GARGER, et al.

FILING DATE

July 26, 2000

GROUP

1656



TECH CENTER 1600/2900

APR 13 2002

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	5,179,023	01/12/93	Calhoun, et al.	435	320.1	07/07/90

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	2.	WO 97/10353	03/20/97	PCT			YES	NO
							X	

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

	3.	Brady, "Fabry Disease", 1169-1178						
	4.	Bowie, et al., "Diciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> <u>247</u> :1306-1310 (1990)						
	5.	Chapman, et al., "Potato virus X as a vector for gene expression in plants," <i>The Plant Journal</i> , <u>2</u> (4):549-557 (1992)						
	6.	Cramer, <i>American Journal of Human Genetics</i> , <u>57</u> (4), 1995, Published for the American of Human Genetic by the University of Chicago Press						
	7.	Desnick, et al., " α -Galactosidase A Deficiency: Fabry Disease," Chapter 89, pgs. 2741-2784						
	8.	Erickson, et al., "BioSynthesis of the Lysosomal Enzyme Glucocerebrosidase," <i>Journal of Biological Chemistry</i> , <u>260</u> (26):14319-14324 (1985)						
	9.	Ferrari, et al., "Cloning and expression of a soluble sialidase from Chinese hamster ovary cells: sequence alignment similarities to bacterial sialidases," <i>Glycobiology</i> , <u>4</u> (3):367-373 (1994)						
	10.	Furbish, et al., "Enzyme replacement therapy in Gaucher's disease: Large-scale purification of glucocerebrosidase suitable for human administration," <i>Proc. Natl. Acad. Sci.</i> , <u>71</u> (8) 3560-3563 (1977)						
	11.	Furbish, et al., "Uptake and Distribution of Placental Glucocerebrosidase in at Hepatic Cells and Effects of Sequential Deglycosylation," <i>Biochemica et Biophysica Acta</i> , <u>673</u> :425-434 (1981)						
	12.	Frank, et al., "Automation of DNA Sequencing Reactions and Related Techniques: A Workstation for Micromanipulation of Liquids," <i>Biotechnology</i> <u>6</u> :1211 (1988)						
	13.	Grace, et al., "Analyses of Catalytic Activity and Inhibitor Binding of Human Acid β -Glucosidase by Site-directed Mutagenesis," <i>The Journal Biological Chemistry</i> , pgs. 6827-6835 (1989)						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

00801.0087.CPUS04

APPLICATION NO.

09/626,127

APPLICANT

Stephen J. GARGER, et al.

FILING DATE

July 26, 2000

GROUP

1656

TECH CENTER 1600/2900

APR 03 2002

RECEIVED

14.	Grace, et al., Analysis of Human Acid β -Glucosidase by Cite-Directed Mutagenesis and Heterologous Expression," <i>The Journal of Biological Chemistry</i> <u>269</u> (3):2283-2291 (1994)
15.	Grace and Grabowski, "Human Acid β -Glucosidase: Glycosylation is Required for Catalytic Activity," <i>Biochemical and Biophysical Research Communications</i> <u>168</u> (2):771-777 (1990)
16.	Grabowski, et al., "Expression of Functional Human Acid β -Glucosidase in COS-1 and <i>Sporoptera frugiperda</i> Cells," <i>Enzyme</i> <u>41</u> :131-142 (1989)
17.	Hopp, et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> <u>6</u> :1204-1210 (1988)
18.	liaskins, et al., Alpha-L-Iduronidase Deficiency in a Cat: A Model of Mucopolysaccharidosis I," <i>Pediat. Res.</i> <u>13</u> :1294-1297 (1979)
19.	Jonsson, et al., "Biosynthesis and naturation of glucocerebrosidase in Gaucher fibroblasts," <i>J. Biochem.</i> <u>104</u> :171-179 (1987)
20.	Kaplan, et al., "Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts," <i>Proc. Natl. Acad. Sci. USA</i> <u>74</u> (5):2026-2030 (1977)
21.	Kornfeld and Mellman, "The Biogenesis of Lysosomes," <i>Annu. Rev. Cell Biol.</i> <u>5</u> :483-525 (1989)
22.	Miyamura, et al., "A Carboxy-terminal Truncation of Human α -Galactosidase A in a Heterozygous Female with Fabry Disease and Modification of the Enzymatic Activity by the Carboxy-terminal Domain," <i>J. Clin. Invest.</i> , <u>98</u> (8):1809-1817 (1996)
23.	Murray, "Lectin-Specific Targeting of Lysosomal Enzymes to Reticuloendothelial Cells," <i>Methods in Enzymology</i> , <u>149</u> :25, 39, 41, 42 (1987)
24.	Ngo, et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pgs. 491-495, K. Merz, Jr. and S. Le Grand, eds. (1994)
25.	Park, et al., "Structure and nucleotide sequence of tomato HMG2 encoding 3-hydroxy-3-methyl-glutaryl coenzyme A reductase," <i>Plant Molecular Biology</i> <u>20</u> :327-331 (1992)
26.	Scott, et al., "Human α -L-iduronidase: cDNA isolation and expression," <i>Proc. Natl. Acad. Sci. USA</i> , <u>88</u> :9695-9699 (1991)
27.	Scott, et al., Structure and Sequence of the Human α -L-Iduronidase Gene <i>Genomics</i> <u>13</u> :1311-1313 (1992)
28.	Schatzle, et al., "Molecular Cloning and Characterization of the Structural Gene Coding for the Developmentally Regulated Lysosomal Enzyme, α -Mannosidase, in <i>Dictyostelium discoideum</i> , <i>The Journal of Biological Chemistry</i> <u>267</u> (6):4000-4007 (1991)
29.	Shull, et al., "Enzyme replacement in a canine model for Hurler syndrome," <i>Proc. Natl. Acad. Sci. USA</i> , <u>91</u> :12917-12941 (1994)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

00801.0087.CPUS04

APPLICATION NO.

09/626,127

APPLICANT

Stephen J. GARGER, et al.

FILING DATE

July 26, 2000

GROUP

1656

TECH CENTER 1600/2900

APR 13 2002

RECEIVED

	30.	Schulz and Schirmer, "Principles of Protein Structure," Springer-Verlag, eds.
	31.	Sijmons, et al. "Production of Correctly Processed Human Serum Albumin in Transgenic Plants," <i>Biotechnology</i> <u>8</u> :217-221 (1990)
	32.	Sorge, et al., "Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA," <i>Proc. Natl. Acad. Sci. USA</i> <u>82</u> :7289-7293 (1987)
	33.	Thornburg, et al., "Wound-inducible expression of a potato inhibitor II-chloramphenicol acetyltransferase gene fusion in transgenic tobacco plants," <i>Proc. Natl. Acad. Sci.</i> <u>84</u> :744-748 (1987)
	34.	Tsuji, et al., "Nucleotide Sequence of cDNA Containing the Complete Coding Sequence for Human Lysosomal Glucocerebrosidase," <i>The Journal of Biological Chemistry</i> <u>261</u> (1):50-53 (1966)
	35.	Vandekerckhove, et al., "Enkephalins Produced in Transgenic Plants Using Modified 2S Seed Storage Proteins," <i>Biotechnology</i> <u>7</u> :929-933 (1989)
	36.	Von Figura and Hasilik, "Lysosomal Enzymes and Their Receptors," <i>Ann. Rev. Biochem.</i> <u>55</u> :167-193 (1986)
	37.	Warner, et al., "Photolabeling of the α -Neuraminidase/ β -Galactosidase Complex From Human Placenta With a Photoreactive Neuraminidase Inhibitor," <i>Biochemical and Biophysical Research Communications</i> <u>173</u> (1):13-19 (1990)
	38.	Weissenborn, "HMB-CoA reductase and terpenoid phytoalexins: Molecular specialization within a complex pathway," <i>Physiologia Plantarum</i> <u>93</u> :393-400 (1995)
	39.	James A. Wells, "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> , <u>29</u> (37):8509-8517 (1990)
	40.	Zhu and Goldstein, "Cloning and characterization of a cDNA encoding chicken liver α -N-acetylgalactosaminidase

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY